Talawar Tx Inc. (“Talawar” or “Talawar Therapeutics”), a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent immunology & inflammatory (I&I) disease drivers in a single therapy, targeting pathways that work together for greater, more durable impact, and JATT II Acquisition Corp (Nasdaq: JATT) (“JATT II”), a special purpose acquisition company focused on building the next wave of life sciences companies, announce they have entered into a definitive business combination agreement. The combined company will operate as Talawar Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol “TLWR”.
Read the full article: Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement //
Source: https://www.prnewswire.com/news-releases/talawar-therapeutics-and-jatt-ii-acquisition-corp-announce-definitive-business-combination-agreement-to-create-publicly-listed-biotechnology-company-developing-potentially-best-in-class-bispecifics-for-ii-diseases-302812610.html